Research and Development news

Here you find the latest news on our research and development activities.
Seite: 1 2 3 1-20 von 56 Dokumente

12/09/14, Research and Development Bayer and DNDi Sign First Agreement to Develop an Innovative Oral Treatment for Human River Blindness more


12/01/14, Research and Development Bayer to Present Latest Data on Its Hematology and Oncology Portfolio Three-year results from the Phase III SPINART study for octocog alfa (Kogenate® FS) in patients with hemophilia A / New data on damoctocog alfa pegol (BAY 94-9027) for the treatment of hemophilia A / Presentations on copanlisib and sorafenib in patients with different hematological cancers more


11/03/14, Research and Development Bayer HealthCare to invest up to USD 25 million in “Versant Venture Capital V” fund more


10/24/14, Research and Development Bayer Forms Alliance with Kyoto University in Japan Collaboration focuses on areas of high unmet medical need / New Bayer “Open Innovation Center Japan” to support alliance more


09/16/14, Research and Development Bayer and Orion Initiate Phase III Trial of Novel Prostate Cancer Agent ODM-201 in Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer more


07/30/14, Research and Development Aflibercept Solution for Injection into the Eye Receives FDA Approval for the Treatment of Diabetic Macular Edema (DME) DME is the third approved indication for aflibercept solution for injection in the U.S. more


07/18/14, Research and Development Two-Year Results From Phase 3 Trial Show Sustained Improvement in Vision for People with Diabetic Macular Edema more


07/03/14, Research and Development Bayer and University of Oxford to Develop Novel Gynecological Therapies more


06/23/14, Research and Development Bayer HealthCare and Dimension Therapeutics to Develop Novel Gene Therapy for Hemophilia A more


05/14/14, Research and Development Bayer HealthCare to unveil 'CoLaborator' in Berlin Incubator for young entrepreneurs in life sciences sets up creative environment for research and innovation in Berlin / First tenants Calico Biolabs, DexLeChem, and provitro already moved in more


05/13/14, Research and Development Bayer HealthCare extends access to clinical trial data Bayer HealthCare joins internet portal “www.clinicalstudydatarequest.com” / Access to clinical trial data for qualified researchers fosters scientific innovation and development of future treatments more


04/25/14, Research and Development Sorafenib Recommended for Approval in the European Union for the Treatment of Differentiated Thyroid Cancer Final decision from European Commission expected by mid-2014 more


04/24/14, Research and Development Positive Results from Phase III DECISION Study of Sorafenib in RAI-Refractory Differentiated Thyroid Cancer Published in The Lancet Sorafenib significantly extended progression-free survival compared to placebo in patients with differentiated thyroid carcinoma (DTC) that is refractory to radioactive iodine treatment (RAI-refractory) / Based on study results, Nexavar is approved in U.S. for RAI-refractory DTC; filing has also been submitted in EU more


04/04/14, Research and Development Bayer to Present New Data on Advancing Oncology Portfolio New Preclinical and Early Clinical Data Evaluating Innovative Compounds in Drug Development more


02/10/14, Research and Development Two-Year Results From Phase III Trial of VEGF Trap-Eye (aflibercept solution for injection) for the Treatment of Diabetic Macular Edema Show Sustained Improvement in Vision more


02/04/14, Research and Development Bayer and German Cancer Research Center (DKFZ) in Strategic Alliance Against Cancer Partners extend existing alliance to develop novel cancer therapies / Joint investment of up to 30 million Euros for collaborative research in oncology over the next five years more


01/13/14, Research and Development Bayer and Regeneron to Develop New Treatment Option for Wet Age-Related Macular Degeneration Joint development of Regeneron’s PDGFR Beta antibody as new candidate for potential combination therapy demonstrates both companies’ strong commitment to ophthalmology / Bayer obtains exclusive commercialization rights outside the U.S., where Bayer and Regeneron will share profits / Regeneron retains full U.S. commercialization rights more


01/08/14, Research and Development Bayer and Peking University Establish New Research Center for Translational Research and Drug Discovery in Beijing Bayer HealthCare and Peking University sign collaboration agreement, Research collaboration demonstrates Bayer’s commitment to China as an important location in its innovation strategy more


12/18/13, Research and Development Bayer HealthCare to Join Not-For-Profit Structural Genomics Consortium to Accelerate Research in Epigenetics more


12/05/13, Research and Development Phase II Data of Bayer’s Novel Cancer Drug Candidate Copanlisib to be Presented First Oral Presentation on Preliminary Phase II Data of Copanlisib (BAY 80-6946) in Patients with Indolent or Aggressive Non-Hodgkin’s Lymphoma more

Seite: 1 2 3 1-20 von 56 Dokumente

Research and Development

More information about the topic Research and Development:

Contact Research Form

Page tools
.
Interactive tool
Grants for Targets
Annual Report 2013
Clinical Trials

open
close
http://www.bayerpharma.com/en/research-and-development/news/index.php

Copyright © Bayer Pharma AG